News
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Your search for apixaban returned 101 results
News
Noncompliance to Apixaban for A-Fib Due to Many Factors
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
News
Oral Anticoagulants Compared for Gastrointestinal Safety
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
News
Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
AHA 2018
Combining NSAIDs With Oral Anticoagulants Increases Bleeding Risk in AF
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
News
Apixaban Seems Safer Than Rivaroxaban for A-Fib
Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.
News
Prophylaxis With Apixaban Feasible for Cancer Patients
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
News
AHA: Concentrates Promising for Reversal of Apixaban
Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.
AHA 2015
Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
Drugs in the Pipeline
Eliquis Reversal Agent Demonstrates Efficacy in Phase 3 Study
Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
